Abivax Surges 20.69% on Eli Lilly Takeover Hints and Nasdaq Index Inclusion Ranks 166th in Market Activity

Market Snapshot

, 2025, , . , reflecting heightened investor interest. , alongside the company’s inclusion in the Nasdaq Biotechnology Index.

Key Drivers

The primary catalyst for Abivax’s rally was the resurfacing of rumors suggesting Eli Lilly representatives met with French Treasury officials in early December to discuss a potential acquisition. French publication La Lettre , sparking investor speculation. While neither Eli Lilly nor Abivax confirmed the rumors—both companies adhering to their policy of not commenting on business development activity—the mere possibility of a deal drove significant buying pressure.

The stock’s momentum was further amplified by its recent clinical achievements. , its drug candidate for ulcerative colitis, . , with favorable safety data. , establishing a foundation of investor confidence. Recent takeover speculation built on this momentum, as analysts highlighted the drug’s commercial potential and the likelihood of strategic interest from larger pharmaceutical firms.

A secondary but notable factor was Abivax’s inclusion in the Nasdaq Biotechnology Index, . This addition, , signaled institutional validation of the company’s market relevance and clinical progress. , . , .

The broader market context also played a role. , . , , . , , , .

However, . , . , leaving room for rapid reversals if the rumors subsided. Nonetheless, , , .

Looking ahead, , . . For now, the interplay of strategic interest, , .